Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamorolone Phase IIb in Duchenne Muscular Dystrophy (VISION-DMD)
NCT03439670Phase 2Completed
- Sponsor
- ReveraGen BioPharma
- Start
- Jun 2018
- Primary completion
- Feb 2021
- Modality
- Orthosteric Ligands
- Countries
- 11
01
Overview
A Phase 2 trial of vamorolone in Duchenne muscular dystrophy (DMD), sponsored by ReveraGen BioPharma. Started Jun 2018; status: completed.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03439670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439670.